F15 Recharge Free Axonics SNM System Clinical Study
Prospektiv, ikke-randomisert, multisenter klinisk evaluering av Recharge Free Axonics SNM-systemet (modell 4101)
Multicenter, prospective, non randomized, single arm evaluation of patients with overactive bladder (OAB) and/or fecal incontinence (FI) employing the Axonics recharge free SNM System.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
A clinical evaluation to comply with new European Medical Device Regulations (EU MDR) guidelines. Multicenter, prospective, non-randomized, single arm study for OAB and/or FI to assess the safety and performance of the Food and Drug Administration (FDA) approved Axonics recharge free sacral neuromodulation (SNM) System, INS Model 4101. The product is currently marketed under the name F15.
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Connecticut
-
Waterford, Connecticut, Forente stater, 06385
- Hartford Healthcare
-
-
Florida
-
Bradenton, Florida, Forente stater, 34205
- Florida Gulf Clinical Research
-
Jacksonville, Florida, Forente stater, 32216
- East Coast Institute of Research
-
Naples, Florida, Forente stater, 34109
- Florida Bladder Institute
-
-
Georgia
-
Macon, Georgia, Forente stater, 31201
- Atrium Health
-
-
Minnesota
-
Coon Rapids, Minnesota, Forente stater, 55433
- Minnesota Urology
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68114
- Adult Pediatric Urology & Urogynecology
-
-
New York
-
New York, New York, Forente stater, 10032
- Columbia University Medical Center
-
-
Oregon
-
Portland, Oregon, Forente stater, 97225
- The Oregon Clinic
-
-
South Carolina
-
Myrtle Beach, South Carolina, Forente stater, 29572
- Southern Shores Urogynecology
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Houston Colon
-
-
-
-
-
Rotterdam, Nederland
- Erasmus Medical Center
-
-
-
-
-
Birmingham, Storbritannia, B15 2TH
- Queen Elizabeth Hospital
-
Bristol, Storbritannia, BS105NB
- Bristol Urological Institute
-
London, Storbritannia, W1G 8PH
- University College London Hospital
-
Sheffield, Storbritannia, S5 7AU
- Northern General Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- 18 years or older
- Primary indication of overactive bladder (OAB) (urinary urgency incontinence (UUI)/ urinary frequency (UF)) or fecal incontinence (FI) who are not candidates for, or who have failed conservative treatment
- Willing and capable to provide written informed consent and agrees to comply with specified evaluations at clinical investigational sites and attend all follow-up assessments for up to 1 year.
Exclusion Criteria:
- Any significant medical condition that is likely to interfere with procedures, device operation, or likely to confound evaluation of endpoints (exclusion of neurological conditions such as multiple sclerosis)
- Any psychiatric or personality disorder that is likely to interfere with procedures at the discretion of the participating physician; this may include poor understanding or compliance with requirements
- Previously underwent an external sacral neuromodulation (SNM) trial and was deemed a non-responder or was previously implanted with a sacral neuromodulation device and did not get therapeutic benefit (a non-responder)
- History of allergic response to titanium, zirconia, polyurethane, epoxy, or silicone
- A female who is breastfeeding
- A female with a positive urine pregnancy test
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Annen: Single Arm - Treatment Groups separated into OAB and FI
Treatment Arm separated into 2 cohorts:
|
Safety and performance/effectiveness assessment of the recharge free Axonics SNM System (Model 4101 in participants with overactive bladder (OAB) or fecal incontinence (FI). |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Performance/Effectiveness - Improvement in Quality of Life scoring (OAB)
Tidsramme: 3 months
|
International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life (ICIQ-OABqol): questions in each subscale are scored by a summed range of 0 to 100, with a higher score indicating better quality of life. Overall score ≥ 10 points from baseline to follow-up is indicative of a clinically meaningful improvement. |
3 months
|
|
Performance/Effectiveness - Improvement in Fecal Incontinence Survey
Tidsramme: 3 months
|
Cleveland Clinic Florida - Fecal Incontinence Score (CCF-FIS): includes 5 items (solid, liquid, gas, wears pad and lifestyle alteration) and 5 frequencies (never = 0, rarely = 1, sometimes = 2, usually = 3, always = 4). Scores range from 0 for full continence to 20 for complete incontinence. A higher score is indicative of the severity of fecal incontinence. |
3 months
|
|
Adverse event reporting (Safety)
Tidsramme: 3 months
|
Device-related, procedure-related and all serious adverse events |
3 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Performance/Effectiveness - Improvement in Quality of Life scoring (OAB)
Tidsramme: 1 year
|
International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life (ICIQ-OABqol): questions in each subscale are scored by a summed range of 0 to 100, with a higher score indicating better quality of life. Overall score ≥ 10 points from baseline to follow-up is indicative of a clinically meaningful improvement. |
1 year
|
|
Performance/Effectiveness - Improvement in Fecal Incontinence Survey
Tidsramme: 1 year
|
Cleveland Clinic Florida - Fecal Incontinence Score (CCF-FIS): includes 5 items (solid, liquid, gas, wears pad and lifestyle alteration) and 5 frequencies (never = 0, rarely = 1, sometimes = 2, usually = 3, always = 4). Scores range from 0 for full continence to 20 for complete incontinence. A higher score is indicative of the severity of fecal incontinence. |
1 year
|
|
Performance/Effectiveness - Improvement in Quality of Life Survey (FI)
Tidsramme: 3 months, 6 months, 1 year
|
Fecal Incontinence Quality of Life (FIQoL): includes four different subscales: lifestyle, coping/behavior, depression/self-perception and embarrassment. Subscale scores range from 1 to 5, with 1 indicating lower functional status of qualify of life. |
3 months, 6 months, 1 year
|
|
Adverse event reporting (Safety)
Tidsramme: 1 year
|
Device-related, procedure-related and all serious adverse events |
1 year
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Prof. Bertil Blok, MD, PhD, Erasmus Medical Center
- Studieleder: Gita Ghadimi, OD, Boston Scientific Corporation
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Mannlige urogenitale sykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Tarmsykdommer
- Vannlatingsforstyrrelser
- Nedre urinveissymptomer
- Urologiske manifestasjoner
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Rektale sykdommer
- Urininkontinens
- Patologiske tilstander, tegn og symptomer
- Tegn og symptomer
- Fekal inkontinens
- Urininkontinens, Urge
Andre studie-ID-numre
Andre studie-ID-numre
- 105-0108
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .